Therapeutics in Heart Failure: Is HFpEF Really the Target?
Time: 9:30 am
day: Day One
Details:
- Status report on therapeutics in HFpEF: comparison with HFrEF and lessons from SGLT2i’s
- Stratifying patients with HFpEF: Which phenotype? Which disease?
- Targeting the treatment population with consideration of metabolic CV disease.
- Implications for clinical trial design.
